Although the cannabinoids have been and continue to be abused by many individuals in our society, their cellular mechanisms of action are not well understood. This lack of understanding has several consequences. First, without information concerning the cellular effects of the cannabinoids, estimates of the potential risks of use of this drug by humans are very difficult to make. Second, the full therapeutic potential of these agents cannot be exploited. Third, the cannabinoids produce a completely unique spectrum of effects so a more thorough understanding of their mechanism of action will provide basic information about brain functioning. A cannabinoid binding site (CB1) that has many of the characteristics of a G protein-coupled receptor has been identified in brain. It is our hypothesis delta 9-tetrahydrocannabinol (THC) and other synthetic cannabimimetics act as inhibitory modulators of neurotransmission as a result of activating the CB1 receptor. In specific, we hypothesize that CB1 activation results in the closure of voltage operated calcium channels. We will use cerebellar granule neurons in primary culture to study this hypothesis. We have three aims in this proposal; first, we will characterize the CB1 receptors of the cerebellum in terms of the efficacy of a variety of CB1 ligands to induce the G coupled state of the receptor and to promote G protein guanine nucleotide exchange. Second, we will determine which G-protein(s) couple to the CB1 receptor in the granule cells.
Our third aim i s to explore the hypothesis that the cannabinoids, acting through CB1, inhibit voltage-regulated calcium channels in cerebellar granule cells. As part of this aim, we will determine the types of calcium channels or currents involved in the effects of the cannabinoids as well as determine whether this effect is pertussis-toxin sensitive. We will also determine whether the effect of the cannabinoids on calcium is due to inhibition of adenylyl cyclase. It is anticipated that the successful completion of these studies will enhance our understanding of the mechanism of action of the cannabinoids and the neurochemical processes with which they interact in the brain.

Agency
National Institute of Health (NIH)
Institute
National Institute on Drug Abuse (NIDA)
Type
Research Project (R01)
Project #
5R01DA008098-02
Application #
2668138
Study Section
Human Development Research Subcommittee (NIDA)
Project Start
1997-04-10
Project End
2000-02-29
Budget Start
1998-03-01
Budget End
1999-02-28
Support Year
2
Fiscal Year
1998
Total Cost
Indirect Cost
Name
Medical College of Wisconsin
Department
Pharmacology
Type
Schools of Medicine
DUNS #
073134603
City
Milwaukee
State
WI
Country
United States
Zip Code
53226
Muthian, S; Rademacher, D J; Roelke, C T et al. (2004) Anandamide content is increased and CB1 cannabinoid receptor blockade is protective during transient, focal cerebral ischemia. Neuroscience 129:743-50
Patel, S; Hillard, C J (2001) Cannabinoid CB(1) receptor agonists produce cerebellar dysfunction in mice. J Pharmacol Exp Ther 297:629-37
Nogueron, M I; Porgilsson, B; Schneider, W E et al. (2001) Cannabinoid receptor agonists inhibit depolarization-induced calcium influx in cerebellar granule neurons. J Neurochem 79:371-81
Hillard, C J (2000) Biochemistry and pharmacology of the endocannabinoids arachidonylethanolamide and 2-arachidonylglycerol. Prostaglandins Other Lipid Mediat 61:18-Mar
Hillard, C J (2000) Endocannabinoids and vascular function. J Pharmacol Exp Ther 294:27-32
Jarrahian, A; Manna, S; Edgemond, W S et al. (2000) Structure-activity relationships among N-arachidonylethanolamine (Anandamide) head group analogues for the anandamide transporter. J Neurochem 74:2597-606
Kearn, C S; Greenberg, M J; DiCamelli, R et al. (1999) Relationships between ligand affinities for the cerebellar cannabinoid receptor CB1 and the induction of GDP/GTP exchange. J Neurochem 72:2379-87
Hillard, C J; Muthian, S; Kearn, C S (1999) Effects of CB(1) cannabinoid receptor activation on cerebellar granule cell nitric oxide synthase activity. FEBS Lett 459:277-81
Hillard, C J; Campbell, W B (1997) Biochemistry and pharmacology of arachidonylethanolamide, a putative endogenous cannabinoid. J Lipid Res 38:2383-98